EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial

David E Kandzari, Michael A Weber iD, Atul Pathak iD, James P Zidar, Manish Saxena iD, Shukri W David iD, Roland E Schmieder iD, Adam J Janas, Christopher Langer, Alexandre Persu iD, Farrell O Mendelsohn, Koen Ameloot und 4 weitere

Circulation · 2024

DOI: 10.1161/circulationaha.124.069291 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation, 2024. Verfasst von David E Kandzari und 15 weiteren Autor:innen. Beteiligte Einrichtung: Piedmont Heart Institute, Atlanta, GA (D.E.K.). Hauptthemen laut MEDLINE: Antihypertensive Agents, Hypertension, Blood Pressure, Kidney. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Ablative Solutions Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Renal denervation (RDN) has demonstrated clinically relevant reductions in blood pressure (BP) among individuals with uncontrolled hypertension despite lifestyle intervention and medications. The safety and effectiveness of alcohol-mediated RDN have not been formally studied in this indication. METHODS: TARGET BP I is a prospective, international, sham-controlled, randomized, patient- and assessor-blinded trial investigating the safety and efficacy of alcohol-mediated RDN. Patients with office systolic BP (SBP) ≥150 and ≤180 mm Hg, office diastolic BP ≥90 mm Hg, and mean 24-hour ambulatory SBP ≥135 and ≤170 mm Hg despite prescription of 2 to 5 antihypertensive medications were enrolled. The primary end point was the baseline-adjusted change in mean 24-hour ambulatory SBP 3 months after the procedure. Secondary end points included mean between-group differences in office and ambulatory BP at additional time points. RESULTS: Among 301 patients randomized 1:1 to RDN or sham control, RDN was associated with a significant reduction in 24-hour ambulatory SBP at 3 months (mean±SD, −10.0±14.2 mm Hg versus −6.8±12.1 mm Hg; treatment difference, −3.2 mm Hg [95% CI, −6.3 to 0.0]; P =0.0487). Subgroup analysis of the primary end point revealed no significant interaction across predefined subgroups. At 3 months, the mean change in office SBP was −12.7±18.3 and −9.7±17.3 mm Hg (difference, −3.0 [95% CI, −7.0 to 1.0]; P =0.173) for RDN and sham, respectively. No significant differences in ambulatory or office diastolic BP were observed. Adverse safety events through 6 months were uncommon, with one instance of accessory renal artery dissection in the RDN group (0.7%). No significant between-group differences in medication changes or patient adherence were identified. CONCLUSIONS: Alcohol-mediated RDN was associated with a modest but statistically significant reduction in 24-hour ambulatory SBP compared with sham control. No significant differences between groups in office BP or 6-month major adverse events were observed. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02910414.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antihypertensive AgentsHypertensionBlood PressureKidneyHumansFemaleMaleMiddle AgedAgedProspective StudiesEthanolTreatment OutcomeBlood Pressure Monitoring, AmbulatorySympathectomyRenal Artery

Stichwörter der Autor:innen

alcoholsantihypertensive agentsdenervationhypertension

Substanzen

Antihypertensive AgentsEthanol

Autor:innen und Institutionen

  • Piedmont Heart Institute, Atlanta, GA (D.E.K.).
  • Division of Cardiovascular Medicine, State University of New York (SUNY), New York (M.A.W.).
  • Department of Cardiovascular Medicine, Princess Grace Hospital and ESH Hypertension Excellence Center, Monaco (A.P.).
  • University of North Carolina (UNC), Rex Healthcare, Raleigh, NC (J.P.Z.).
  • Barts Health NHS Trust, Queen Mary University of London, United Kingdom (M.S.).
  • Ascension Providence Hospital, Southfield, MI (S.W.D.).

ORCID-Profile: Michael A Weber, Atul Pathak, Manish Saxena, Shukri W David, Roland E Schmieder, Alexandre Persu, Malcolm Foster, Helen Parise, Felix Mahfoud

Förderung

  • Ablative Solutions Inc.

Zitieren

APA

Kandzari, D. E., Weber, M. A., Pathak, A., Zidar, J. P., Saxena, M., David, S. W., Schmieder, R. E., Janas, A. J., Langer, C., Persu, A., Mendelsohn, F. O., Ameloot, K., Foster, M., Fischell, T. A., Parise, H., & Mahfoud, F. (2024). Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial. Circulation. https://doi.org/10.1161/circulationaha.124.069291

Vancouver

Kandzari DE, Weber MA, Pathak A, Zidar JP, Saxena M, David SW, et al. Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial. Circulation. 2024. doi:10.1161/circulationaha.124.069291

BibTeX
@article{Kandzari2024,
  author = {Kandzari, David E and Weber, Michael A and Pathak, Atul and Zidar, James P and Saxena, Manish and David, Shukri W and Schmieder, Roland E and Janas, Adam J and Langer, Christopher and Persu, Alexandre and Mendelsohn, Farrell O and Ameloot, Koen and Foster, Malcolm and Fischell, Tim A and Parise, Helen and Mahfoud, Felix},
  title = {Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial},
  journal = {Circulation},
  year = {2024},
  doi = {10.1161/circulationaha.124.069291}
}
Kostenlos starten →